Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
golidocitinib + itraconazole
- Development stage
- Unknown
- Lead developer
- Dizal Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AZD4205 + itraconazole refers to a clinical drug-drug interaction (DDI) study pairing involving golidocitinib (AZD4205), a potent and highly selective oral Janus kinase 1 (JAK1) inhibitor, and itraconazole, a strong CYP3A4 inhibitor. Golidocitinib, developed by Dizal Pharmaceuticals, is a small molecule targeting the JAK/STAT signaling pathway and is indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). The combination was specifically evaluated in a Phase 1 clinical trial (NCT05486949) to characterize the pharmacokinetic impact of CYP3A4 inhibition on golidocitinib exposure in healthy adult subjects, as golidocitinib is primarily metabolized by the cytochrome P450 system.
- Other names
- golidocitinib + itraconazole
02
Targets
TYK2 (Tyrosine kinase 2)JAK2 (Janus kinase 2)CYP51A1 (Sterol 14α-demethylase)JAK1 (Janus kinase 1)JAK3 (Janus kinase 3)CYP3A4 (Cytochrome P450 3A4)
Beyond the preview
Go deeper on golidocitinib + itraconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on golidocitinib + itraconazole.